Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer—The GCIG Symptom Benefit Study

BACKGROUND. Clinicians and patients often overestimate the benefits of chemotherapy, and overall survival (OS), in platinum resistant/refractory ovarian cancer (PRROC). This study sought to determine aspects of health‐related quality of life and clinicopathological characteristics before starting ch...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Roncolato, Felicia T., Joly, Florence, O'Connell, Rachel, Lanceley, Anne, Hilpert, Felix, Buizen, Luke, Okamoto, Aikou, Aotani, Eriko, Pignata, Sandro, Donnellan, Paul, Oza, Amit, Avall‐Lundqvist, Elisabeth, Berek, Jonathan S., Heitz, Florian, Feeney, Amanda, Berton‐Rigaud, Dominique, Stockler, Martin R., King, Madeleine, Friedlander, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Gynecologic Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5599194/
https://ncbi.nlm.nih.gov/pubmed/28596446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0047
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados